PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Sintilimab
Sponsor: First Affiliated Hospital, Sun Yat-Sen University